Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Mind Medicine Mindmed Inc
(NQ:
MNMD
)
6.020
+0.045 (+0.75%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mind Medicine Mindmed Inc
< Previous
1
2
...
25
26
27
28
29
30
31
32
Next >
Investors Turning to Psychedelic Market as Renaissance Continues into New Wave of Diseases
September 27, 2021
Via
Investor Brand Network
Topics
Cannabis
Exposures
Cannabis
Senate Bill Decriminalizing Psychedelics Could Help Reverse Some “War on Drugs” Impacts
September 22, 2021
Via
FinancialNewsMedia
Which Psychedelic Stock ETF Is Right For You?
September 18, 2021
This week the AdvisorShares Psychedelics ETF began trading on the NYSE Arca. Here we compare the make-up of the now 3 psychedelic stock ETFs and two tracking indexes.
Via
Talk Markets
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
July 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...
Via
Benzinga
Exposures
COVID-19
Compass: Psychedelics Unicorn Expands Portfolio Beyond Psilocybin Into Psychedelics 2.0
September 15, 2021
Psychedelics biotech company Compass Pathways (NASDAQ:CMPS...
Via
Benzinga
Psychedelic Medicine's Top CEOs: Who's Running The Biggest Companies In This Booming Industry?
September 09, 2021
By Natan Ponieman and Javier Hasse The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate...
Via
Benzinga
National Suicide Prevention Week Shines Light on Psychedelic Treatments
September 09, 2021
Via
FinancialNewsMedia
Psyched: Field Trip Gets $20 Price Target, DEA Seeks To Increase Psilocybin Production Limits, Synthesis Closes $7.25M Series A
September 07, 2021
Contents
Via
Benzinga
Psychedelic Drug Industry Report Card For 2021
September 01, 2021
In assessing the psychedelic drug industry, a primary focus for investors is drug development.
Via
Talk Markets
EXCLUSIVE: Kevin O'Leary Unpacks Deal Flow, Investments, Perspectives On Disruptive Innovation
August 31, 2021
A lot has changed since Benzinga last spoke with Kevin O’Leary, businessman, author, "Shark Tank's" Mr...
Via
Benzinga
Psyched: Cybin Gets $9 Price Target, FSD Pharma Acquires Lucid, New Trials From Psilera, Awakn, PharmaDrug And Braxia, California Bill Put On Hold
August 30, 2021
Contents
Via
Benzinga
Magic Mushroom Drug Stock Performances YTD
August 29, 2021
Of the 35 companies involved in clinical stage research of psychedelic substances, 20 are researching the benefits of psilocybin, the primary psychoactive ingredient in “magic mushrooms”.
Via
Talk Markets
MindMed Teams Up With Forian To Improve Real-World Evidence Data To Help Psychiatric Patients
August 24, 2021
Psychedelics-focused medicines company Mind Medicine Inc. (NASDAQ:
Via
Benzinga
Cramer Weighs In On RealReal, Affirm Holdings And More
August 17, 2021
On CNBC's "Mad Money Lightning Round," Jim Cramer said no to RealReal Inc (NASDAQ: REAL). He is not a buyer because there are too many of these guys. Mind Medicine (...
Via
Benzinga
Push the Boundaries of DMT Therapy with Mind Medicine
August 16, 2021
Ready to explore an under-developed area of psychedelic medicine? If so, then consider a long position in low-priced MNMD stock.
Via
InvestorPlace
Topics
Cannabis
Exposures
Cannabis
MindMed Reports Q2 Earnings With Net Loss of $36M And Cash Balance Of $157M To Continue With Its Clinical Pipeline
August 16, 2021
The psychedelics-focused medicines company MindMed (NASDAQ:
Via
Benzinga
No Matter How the Pandemic Rolls, Mind Medicine Will Prevail
August 11, 2021
While MNMD stock is controversial due to its underlying psychedelic therapies, the broader narrative is exceptionally compelling.
Via
InvestorPlace
Which Psychedelic Drug Has The Most Commercial Potential?
August 10, 2021
As the Mental Health Crisis has become a mental health pandemic, clinical research on psychedelic drugs is showing that these substances are the best – and only – option to address this crisis.
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2021
August 05, 2021
Upgrades Stephens & Co. upgraded the previous rating for Roku Inc (NASDAQ:
Via
Benzinga
Psyched: Field Trip Uplists To Nasdaq, MindMed To Study DMT, Atai Launches New Subsidiary, AOC's Psychedelics Amendment Rejected
August 02, 2021
Last week in Psychedelics:
Via
Benzinga
Another Psychedelic Stock Debuts, As This One Sets Up In A Base
July 29, 2021
Field Trip Health dipped in its first day on the Nasdaq, making it the latest psychedelics company to hit a big U.S. exchange.
Via
Investor's Business Daily
MindMed Leverages Ayahuasca's Ingredient DMT In Psychedelic-Inspired Therapies, Launches Trials With 30 Subjects
July 29, 2021
Psychoactive brew ayahuasca is known for having a fast-onset antidepressant effect. With serotonergic psychedelics, such...
Via
Benzinga
Field Trip Health Heads To The Nasdaq As Wall Street Opens Up To "Psychedelics Renaissance"
July 23, 2021
Excitement around psychedelics grows as major U.S. exchanges make room for more companies in the sector. On Friday,
Via
Benzinga
Psychedelics Gain More Traction as New Research Aims to Address Chronic Pain and Mental Illness
July 21, 2021
Via
FinancialNewsMedia
Topics
Law Enforcement
Exposures
Legal
Mind Medicine Has More Obstacles Than Opportunities
July 20, 2021
MNMD stock could revolutionize mental healthcare with its novel therapeutics, but there are currently too many risks with its business.
Via
InvestorPlace
Psychedelic Decriminalization Creating Market Opportunities
July 12, 2021
Via
FinancialNewsMedia
Topics
Cannabis
Law Enforcement
Exposures
Cannabis
Legal
Psyched: Numinus, MindMed, Cybin Reach Milestones, Harvard To Study Psychedelics Law, Michael Pollan Dives Into Mescaline
July 12, 2021
Michael Pollan’s New Book Takes A Deep Dive Into Mescaline – Will This Be A Turning Point For The Recognition And Study of&n...
Via
Benzinga
How To Invest In "Magic Mushrooms" (Psychedelics)
July 09, 2021
A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest.
Via
Talk Markets
MindMed Stock Is Overvalued and Too Risky to Own
July 08, 2021
MindMed can be the future of psychedelic medicines, but without cash flow from revenue, MNMD stock is nothing to get excited about.
Via
InvestorPlace
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
July 07, 2021
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Ps...
Via
Benzinga
< Previous
1
2
...
25
26
27
28
29
30
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.